tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Bristol Myers price target raised to $75 from $66 at Piper Sandler
PremiumThe FlyBristol Myers price target raised to $75 from $66 at Piper Sandler
4d ago
Bristol Myers initiated with an Overweight at Barclays
Premium
The Fly
Bristol Myers initiated with an Overweight at Barclays
8d ago
FDA to begin requiring on clinical trial
Premium
The Fly
FDA to begin requiring on clinical trial
9d ago
Bristol-Myers Squibb: Solid Near-Term Execution and 2026 EPS Boost from Eliquis, but Limited Long-Term Visibility Supports Hold Rating
PremiumRatingsBristol-Myers Squibb: Solid Near-Term Execution and 2026 EPS Boost from Eliquis, but Limited Long-Term Visibility Supports Hold Rating
17d ago
Bristol Myers price target raised to $40 from $37 at Morgan Stanley
Premium
The Fly
Bristol Myers price target raised to $40 from $37 at Morgan Stanley
21d ago
Trump Trade: Argentina says U.S. to cut hundreds of tariffs
Premium
The Fly
Trump Trade: Argentina says U.S. to cut hundreds of tariffs
21d ago
Reiterating Buy on Bristol-Myers Squibb: Near-Term Outperformance and Pipeline-Driven Upside Support Higher $68 Target
PremiumRatingsReiterating Buy on Bristol-Myers Squibb: Near-Term Outperformance and Pipeline-Driven Upside Support Higher $68 Target
22d ago
Bristol-Myers Squibb Bets On New Growth Engines
Premium
Company Announcements
Bristol-Myers Squibb Bets On New Growth Engines
22d ago
Reiterating Buy on Bristol-Myers Squibb: Milvexian’s Validated FXIa Mechanism and Underappreciated Stroke Prevention Upside Support $65 Target
Premium
Ratings
Reiterating Buy on Bristol-Myers Squibb: Milvexian’s Validated FXIa Mechanism and Underappreciated Stroke Prevention Upside Support $65 Target
22d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100